<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4645462</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P154</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P154</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Hellmann</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Ramalingam</surname><given-names>Suresh</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Reck</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>O'Byrne</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Paz-Ares</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Harbison</surname><given-names>Christopher T</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Bhagavatheeswaran</surname><given-names>Prabhu</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Nathan</surname><given-names>Faith</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Brahmer</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib></contrib-group><aff id="I1"><label>1</label>Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff><aff id="I2"><label>2</label>Winship Cancer Institute, Emory University, Atlanta, GA, USA</aff><aff id="I3"><label>3</label>Krankenhaus Grosshansdorf Gmbh, Ahrensburg, Germany</aff><aff id="I4"><label>4</label>Cancer Services, Princess Alexandra Hospital, Brisbane, QLD, Australia</aff><aff id="I5"><label>5</label>Hospital Universitario Virgen del Rocio, Sevilla, Spain</aff><aff id="I6"><label>6</label>Bristol-Myers Squibb, Princeton, NJ, USA</aff><aff id="I7"><label>7</label>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P154</fpage><lpage>P154</lpage><permissions><copyright-statement>Copyright © 2015 Hellmann et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Hellmann et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P154"></self-uri><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title><offsets xml_i="5161" xml_f="5171" txt_i="7" txt_f="17">Background</offsets></title><p><offsets xml_i="5182" xml_f="6293" txt_i="18" txt_f="1129">Patients with advanced NSCLC are treated with first-line PT-DC, which is associated with a median OS of 8–10 months and 1-year and 2-year survival rates of 30–40% and 10–15%, respectively. Nivolumab (a fully human IgG4 anti-programmed death-1 immune checkpoint inhibitor antibody) alone and in combination with ipilimumab (a fully human IgG4 cytotoxic T-lymphocyte antigen-4 immune checkpoint inhibitor antibody) has demonstrated encouraging clinical benefit across multiple tumor types. Two randomized Phase III trials demonstrated superior survival with nivolumab vs docetaxel in previously-treated patients with advanced squamous (SQ) (CheckMate 017) and non-squamous (non-SQ) NSCLC (CheckMate 057). Preliminary results of a Phase I study (CheckMate 012) of nivolumab with or without ipilimumab demonstrate acceptable safety and encouraging activity in first-line metastatic NSCLC across histologies. This Phase III trial (CheckMate 227) evaluates nivolumab monotherapy and nivolumab plus ipilimumab combination regimens vs PT-DC in patients with chemotherapy-naïve stage IV or recurrent SQ and non-SQ NSCLC.</offsets></p></sec><sec><title><offsets xml_i="6315" xml_f="6322" txt_i="1131" txt_f="1138">Methods</offsets></title><p><offsets xml_i="6333" xml_f="7440" txt_i="1139" txt_f="2246">Adult patients with stage IV or recurrent NSCLC, ECOG performance status ≤1, no prior systemic anti-cancer therapy, and measureable disease per RECIST version 1.1 are eligible. Tissue will be evaluated for programmed death-ligand 1 (PD-L1) expression during screening. Patients who have untreated CNS metastases are ineligible. Patients will be randomized to nivolumab monotherapy, nivolumab plus ipilimumab combination regimens, or PT-DC. PT-DC will be administered according to histology (gemcitabine with cisplatin or carboplatin for SQ and pemetrexed with cisplatin or carboplatin for non-SQ). Patients will receive treatment until progression or unacceptable toxicity. The co-primary endpoints are overall survival and progression-free survival in patients receiving nivolumab monotherapy or nivolumab plus ipilimumab combination regimens vs patients receiving PT-DC. Secondary endpoints include objective response rate in nivolumab monotherapy or nivolumab plus ipilimumab combination regimens vs PT-DC and disease related symptom improvement measured by the Lung Cancer Symptom Scale in all patients.</offsets></p></sec><sec><title><offsets xml_i="7462" xml_f="7480" txt_i="2248" txt_f="2266">Trial registration</offsets></title><p><offsets xml_i="7491" xml_f="7533" txt_i="2267" txt_f="2309">ClinicalTrials.gov identifier NCT02477826.</offsets></p></sec></body></article>